Together, these data suggest that pharmacologically blocking MARCO could recover the tumor recognition capacity of TAMs and boost the efficiency of ICB treatment in RCC, making it a promising therapeutic strategy for the treatment of RCC, especially for the ICB‐resistant tumors. The gene discussed is MARCO; the disease is renal cell adenocarcinoma.